相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019
P. Heffeter et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2014)
Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study
Aviva Levina et al.
CHEMISTRY-A EUROPEAN JOURNAL (2013)
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Petra Heffeter et al.
EUROPEAN JOURNAL OF CANCER (2013)
X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)
Alfred A. Hummer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The Anticancer Ruthenium Complex KP1019 Induces DNA Damage, Leading to Cell Cycle Delay and Cell Death in Saccharomyces cerevisiae
Shannon K. Stevens et al.
MOLECULAR PHARMACOLOGY (2013)
Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates
A. Bergamo et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells
Jade B. Aitken et al.
METALLOMICS (2012)
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Ute Jungwirth et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting
Min Ni et al.
BIOCHEMICAL JOURNAL (2011)
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019
Caroline Bartel et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2011)
LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma
Anna K. Bytzek et al.
METALLOMICS (2011)
Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin
Michael Groessl et al.
METALLOMICS (2011)
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Petra Heffeter et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2010)
Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry
Michael Groessl et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2010)
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study
Frederike Lentz et al.
ANTI-CANCER DRUGS (2009)
KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger et al.
CHEMISTRY & BIODIVERSITY (2008)
Resistance against novel anticancer metal compounds: Differences and similarities
Petra Heffeter et al.
DRUG RESISTANCE UPDATES (2008)
Electron-transfer activated metal-based anticancer drugs
Erwin Reisner et al.
INORGANICA CHIMICA ACTA (2008)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Probing the stability of serum protein-ruthenium (III) drug adducts in the presence of extracellular reductants using CE
Andrej R. Timerbaev et al.
ELECTROPHORESIS (2007)
Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP
P Schluga et al.
DALTON TRANSACTIONS (2006)
The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells
S Kapitza et al.
CANCER LETTERS (2005)
Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole) ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis
AR Timerbaev et al.
ANALYTICAL BIOCHEMISTRY (2005)
Redox-active antineoplastic ruthenium complexes with indazole: Correlation of in vitro potency and reduction potential
MA Jakupec et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells
F Frausin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
S Kapitza et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Reactions of potent antitumor complex trans-[RuIIICl4(indazole)2]-with a DNA-relevant nucleobase and thioethers:: Insight into biological action
A Egger et al.
INORGANIC CHEMISTRY (2005)
Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium( III) compound with plasma proteins
M Sulyok et al.
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY (2005)
Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (FFC14A)
P Heffeter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy
M Pongratz et al.
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY (2004)
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A
G Sava et al.
EUROPEAN JOURNAL OF CANCER (2004)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins
F Piccioli et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2004)
Antianglogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
L Morbidelli et al.
BRITISH JOURNAL OF CANCER (2003)
Formation and transfer of disulphide bonds in living cells
CS Sevier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Recycling processes of cellular ascorbate generate oxidative stress in pancreatic tissues in in vitro system
S Brown et al.
ENDOCRINE (2002)
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
A Vacca et al.
BRITISH JOURNAL OF CANCER (2002)
Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple
FQ Schafer et al.
FREE RADICAL BIOLOGY AND MEDICINE (2001)
Hydrolysis of the tumor-inhibiting ruthenium[lll) complexes Hlm trans-[RnCl4(im)2] and Hlnd trans[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS
A Küng et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2001)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
H Maeda et al.
JOURNAL OF CONTROLLED RELEASE (2000)
分享论文
